Distinct forebrain and caudal brainstem contributions to the neuropeptide Y mediation of ghrelin hyperphagia.
Neuropeptide Y (NPY) has been implicated in the downstream mediation of ghrelin hyperphagia, with the site of action for both peptides considered to be intrinsic to the hypothalamus. Here, however, we observed robust hyperphagia with caudal brainstem (CBS) (fourth intracerebroventricular) ghrelin delivery and, moreover, that this response was reversed with coadministration of either of two NPY receptor antagonists (1229U91 and D-Tyr27,36, D-Thr32 NPY27-36) with contrasting NPY receptor subtype-binding properties. The same results were obtained after forebrain (third intracerebroventricular) administration, but the sites for both ghrelin and antagonist action were open to question, given the caudal flow of cerebrospinal fluid (CSF) through the ventricular system. To control for this, we occluded the cerebral aqueduct to restrict CSF flow between the forebrain and CBS ventricles and tested all combinations (same and cross ventricle) of ghrelin (150 pmol/1 microl) and NPY receptor antagonist delivery. With fourth intracerebroventricular ghrelin delivery after aqueduct occlusion, preadministration of either of the two antagonists through the same cannula reversed the hyperphagic response but neither was effective when delivered to the third ventricle. With third intracerebroventricular ghrelin administration, however, 1229U91 reversed the ingestive response only when delivered to the fourth ventricle, whereas D-Tyr27,36) D-Thr32 NPY27-36 was effective only when delivered to the forebrain. These results demonstrate distinct mediating pathways (due to location and subtypes of relevant NPY receptor) for the hyperphagic response driven separately by forebrain and CBS ghrelin administration.
Department of Psychology, University of Pennsylvania, 3720 Walnut St., Philadelphia, PA 19104, USA. lucyhf@sas.upenn.edu
Lucy F
LF
Faulconbridge
Harvey J
HJ
Grill
Joel M
JM
Kaplan
D000818:Animals; D001933:Brain Stem / Q000503:physiopathology*; D002552:Cerebral Ventricles / Q000187:drug effects; D004195:Disease Models, Animal; D054439:Ghrelin; D006963:Hyperphagia / Q000503:physiopathology*; D007276:Injections, Intraventricular; D008297:Male; D009478:Neuropeptide Y / Q000037:antagonists & inhibitors*; D036361:Peptide Hormones / Q000494:pharmacology* / Q000502:physiology; D010456:Peptides, Cyclic / Q000494:pharmacology; D016548:Prosencephalon / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
C097287:1229U91; D054439:Ghrelin; D009478:Neuropeptide Y; D036361:Peptide Hormones; D010456:Peptides, Cyclic